

-continued

<223> OTHER INFORMATION: His or Phe
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (15)..(15)
 <223> OTHER INFORMATION: Glu or Asp

<400> SEQUENCE: 55

Glu Ile Arg Ser Xaa Ser Asp Xaa Xaa Ala Thr Xaa Tyr Ala Xaa Ala
 1 5 10 15

Val Lys Gly

<210> SEQ ID NO 56
 <211> LENGTH: 6
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 6xHis tag

<400> SEQUENCE: 56

His His His His His His
 1 5

<210> SEQ ID NO 57
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide

<400> SEQUENCE: 57

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

We claim:

1. An isolated human or humanized anti-CGRP antagonist antibody with a binding affinity (K_D) to human α -CGRP of 50 nM or less as measured by surface plasmon resonance at 37° C.
2. The anti-CGRP antagonist antibody of claim 1 wherein the anti-CGRP antagonist antibody binds a C-terminal fragment having amino acids 25-37 of CGRP.
3. The anti-CGRP antagonist antibody of claim 2, wherein the anti-CGRP antagonist antibody binds a C-terminal epitope within amino acids 25-37 of CGRP.
4. The antibody according to claim 1, wherein the antibody is an IgG, an IgM, an IgE, an IgA, or an IgD molecule, or is derived therefrom.
5. The anti-CGRP antagonist antibody according to claim 1, wherein said antibody comprises an Fc region.
6. The anti-CGRP antagonist antibody according to claim 5, wherein said Fc region comprises an impaired effector function.
7. The anti-CGRP antagonist antibody according to claim 1, wherein said antibody is a humanized antibody.
8. A pharmaceutical composition comprising the antibody according to claim 1 and a pharmaceutically acceptable excipient.
9. The anti-CGRP antagonist antibody according to claim 1, wherein the antibody is formulated for systemic administration.

* * * * *